BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L. R. Chirieac, R. F. Padera, G. I. Shapiro, A. Baum, F. Himmelsbach, W. J. Rettig, M. Meyerson, F. Solca, H. Greulich, K. K. Wong

Research output: Contribution to journalArticle

937 Citations (Scopus)

Abstract

Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.

Original languageEnglish (US)
Pages (from-to)4702-4711
Number of pages10
JournalOncogene
Volume27
Issue number34
DOIs
StatePublished - Aug 7 2008

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Quinazolines
BIBW 2992
Mutation
Tumor Cell Line
Oncogenes
Point Mutation
Heterografts
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Neoplasms
Protein Isoforms
Phosphotransferases
Up-Regulation
Adenosine Triphosphate
Survival
Therapeutics

Keywords

  • BIBW2992
  • EGFR
  • HER2
  • Lung cancer
  • Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., ... Wong, K. K. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702-4711. https://doi.org/10.1038/onc.2008.109

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. / Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K.

In: Oncogene, Vol. 27, No. 34, 07.08.2008, p. 4702-4711.

Research output: Contribution to journalArticle

Li, D, Ambrogio, L, Shimamura, T, Kubo, S, Takahashi, M, Chirieac, LR, Padera, RF, Shapiro, GI, Baum, A, Himmelsbach, F, Rettig, WJ, Meyerson, M, Solca, F, Greulich, H & Wong, KK 2008, 'BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models', Oncogene, vol. 27, no. 34, pp. 4702-4711. https://doi.org/10.1038/onc.2008.109
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-4711. https://doi.org/10.1038/onc.2008.109
Li, D. ; Ambrogio, L. ; Shimamura, T. ; Kubo, S. ; Takahashi, M. ; Chirieac, L. R. ; Padera, R. F. ; Shapiro, G. I. ; Baum, A. ; Himmelsbach, F. ; Rettig, W. J. ; Meyerson, M. ; Solca, F. ; Greulich, H. ; Wong, K. K. / BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. In: Oncogene. 2008 ; Vol. 27, No. 34. pp. 4702-4711.
@article{06e8c23f372949a88af6267c6d960f65,
title = "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models",
abstract = "Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.",
keywords = "BIBW2992, EGFR, HER2, Lung cancer, Therapeutics",
author = "D. Li and L. Ambrogio and T. Shimamura and S. Kubo and M. Takahashi and Chirieac, {L. R.} and Padera, {R. F.} and Shapiro, {G. I.} and A. Baum and F. Himmelsbach and Rettig, {W. J.} and M. Meyerson and F. Solca and H. Greulich and Wong, {K. K.}",
year = "2008",
month = "8",
day = "7",
doi = "10.1038/onc.2008.109",
language = "English (US)",
volume = "27",
pages = "4702--4711",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "34",

}

TY - JOUR

T1 - BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

AU - Li, D.

AU - Ambrogio, L.

AU - Shimamura, T.

AU - Kubo, S.

AU - Takahashi, M.

AU - Chirieac, L. R.

AU - Padera, R. F.

AU - Shapiro, G. I.

AU - Baum, A.

AU - Himmelsbach, F.

AU - Rettig, W. J.

AU - Meyerson, M.

AU - Solca, F.

AU - Greulich, H.

AU - Wong, K. K.

PY - 2008/8/7

Y1 - 2008/8/7

N2 - Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.

AB - Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.

KW - BIBW2992

KW - EGFR

KW - HER2

KW - Lung cancer

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=49149118719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149118719&partnerID=8YFLogxK

U2 - 10.1038/onc.2008.109

DO - 10.1038/onc.2008.109

M3 - Article

C2 - 18408761

AN - SCOPUS:49149118719

VL - 27

SP - 4702

EP - 4711

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 34

ER -